Global Clinical Trials Review on Bone Metastasis, H1, 2013

GlobalData''s clinical trial report, “Bone Metastasis Global Clinical Trials Review, H1, 2013" provides data on the Bone Metastasis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bone Metastasis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bone Metastasis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData''s team of industry experts.

Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Buy a copy of this report @ http://www.reportsnreports.com/contacts/RequestSample.aspx?name=215426 

Table of Contents 
List of Tables 5
List of Figures 6
Introduction 7
Bone Metastasis 7
Report Guidance 7
Clinical Trials by Region 8
Clinical Trials by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by BRIC Nations 16
Clinical Trials by G7 Nations 17
Clinical Trials in G7 Nations by Trial Status 18
Clinical Trials by E7 Nations 19
Clinical Trials in E7 Nations by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Unaccomplished Trials of Bone Metastasis 24
Subjects Recruited Over a Period of Time 26
Prominent Sponsors 27
Top Companies Participating in Bone Metastasis Therapeutics Clinical Trials 29
Prominent Drug Comparison 31
Clinical Trial Profiles 32
Clinical Trial Overview of Top Companies 32
Novartis AG 32
Clinical Trial Overview of Novartis AG 32
Algeta ASA 34
Clinical Trial Overview of Algeta ASA 34
F. Hoffmann-La Roche Ltd. 35
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 35
Amgen Inc. 36
Clinical Trial Overview of Amgen Inc. 36
Merck & Co., Inc. 37
Clinical Trial Overview of Merck & Co., Inc. 37
Pfizer Inc. 38
Clinical Trial Overview of Pfizer Inc. 38
Hoffmann-La Roche Inc. 39
Clinical Trial Overview of Hoffmann-La Roche Inc. 39
Novartis Pharmaceuticals Corporation 40
Clinical Trial Overview of Novartis Pharmaceuticals Corporation 40
Bayer AG 41
Clinical Trial Overview of Bayer AG 41
Medivir AB 42
Clinical Trial Overview of Medivir AB 42
Insmed Incorporated 43
Clinical Trial Overview of Insmed Incorporated 43
Merck KGaA 44
Clinical Trial Overview of Merck KGaA 44
Galil Medical Ltd. 45
Clinical Trial Overview of Galil Medical Ltd. 45
AstraZeneca PLC 46
Clinical Trial Overview of AstraZeneca PLC 46
Celsion Corporation 47
Clinical Trial Overview of Celsion Corporation 47
Bristol-Myers Squibb Company 48
Clinical Trial Overview of Bristol-Myers Squibb Company 48
Clinical Trial Overview of Top Universities / Institutes / Hospitals 49
The University of Texas M. D. Anderson Cancer Center 49
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 49
Sun Yat-sen University 50
Clinical Trial Overview of Sun Yat-sen University 50
University Health Network 51
Clinical Trial Overview of University Health Network 51
Memorial Sloan Kettering Cancer Center 52
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 52
Massachusetts General Hospital 53
Clinical Trial Overview of Massachusetts General Hospital 53
UMC Utrecht Holding BV 54
Clinical Trial Overview of UMC Utrecht Holding BV 54
Virginia Commonwealth University 55
Clinical Trial Overview of Virginia Commonwealth University 55
Rambam Health Care Campus 56
Clinical Trial Overview of Rambam Health Care Campus 56
Wake Forest University 57
Clinical Trial Overview of Wake Forest University 57
University of Virginia 58
Clinical Trial Overview of University of Virginia 58
FUDAN University 59
Clinical Trial Overview of FUDAN University 59
The University of British Columbia 60
Clinical Trial Overview of The University of British Columbia 60
VU University Medical Center 61
Clinical Trial Overview of VU University Medical Center 61
The University of Texas Health Science Center at San Antonio 62
Clinical Trial Overview of The University of Texas Health Science Center at San Antonio 62
National Taiwan University Hospital 63
Clinical Trial Overview of National Taiwan University Hospital 63
Case Comprehensive Cancer Center 64
Clinical Trial Overview of Case Comprehensive Cancer Center 64
Sunnybrook Health Sciences Centre 65
Clinical Trial Overview of Sunnybrook Health Sciences Centre 65
University of Michigan 66
Clinical Trial Overview of University of Michigan 66
Chinese University of Hong Kong 67
Clinical Trial Overview of Chinese University of Hong Kong 67
Queen''s University 68
Clinical Trial Overview of Queen''s University 68
Five Key Clinical Profiles 69
Appendix 142
Abbreviations 142
Definitions 142
Research Methodology 143
Secondary Research 144
About GlobalData 144
Contact Us 144
Disclaimer 144
Source 145

Request a Sample of this report @ http://www.reportsnreports.com/contacts/RequestSample.aspx?name=215426

Accelerating Drugs to Market - Despite Challenges, Adaptive Clinical Trials Reduce Drug Development Costs and Time to Market

GBI Research’s new report, “Accelerating Drugs to Market - Despite Challenges, Adaptive Clinical Trials Reduce Drug Development Costs and Time to Market”, presents various tools and strategies which can accelerate a drug to the market. In this report, GBI Research has studied various hurdles at different stages of drug development that can halt a drug’s development. The report provides detailed information about the need for accelerated drug development. Declining R&D productivity is highlighted as one of the major needs to be addressed. The report outlines misconceptions regarding accelerated drug development; one such major misconception is the cost of development. The cost of an accelerated development program can be effectively managed by implementing a structured and complete program. The report highlights major strategies adopted by pharmaceutical companies to accelerate drug development. The adoption of the latest technologies in lead generation, preclinical stages, and the use of adaptive designs in late phase studies are regarded as tools to accelerate drugs through these stages of development.

Buy a copy of this report @ http://www.reportsnreports.com/reports/192514-accelerating-drugs-to-market-despite-challenges-adaptive-clinical-trials-reduce-drug-development-costs-and-time-to-market.html

Report Details:
Published: September 2012
No. of Pages: 63
Price:Single User License:US$3500 Corporate User License:US$10500



The process of drug development starts from the initial discovery and ends with a final medication. This is an expensive, lengthy and incremental process. The main objective of the process is to identify a molecule with the potential for producing the desired effect in the human body, and to establish the quality, safety and efficacy of the molecule for treating patients. In the present scenario drug development takes about 12 years, for a molecule to progress from the laboratory and enter the pharmaceutical market. It is estimated that out of 5,000 compounds which enter the preclinical stage of development, only five compounds will be successful enough to be tested on humans, and only one among them will be approved. The slow pace of drug development greatly affects the pharmaceutical industry and patients who are in need of new therapeutics to treat their illness.

The current process of drug development begins with the synthesis of molecules, which targets specific proteins in living cells. It is followed by in vitro tests to identify any specific toxicity associated with the synthesized molecules. The compounds which make it through this stage will go further and will be tested for in vivo toxicology studies. The information gathered from these studies is utilized for planning and conducting clinical trials in human subjects.

It is important for biopharmaceutical companies to launch their products more quickly in the market, as this will lead to early revenue generation from the product. As a large number of drugs fail at the later stages of drug development, pharmaceutical companies try to maintain their revenues by launching new drugs at the earliest possible time. The decline in the total number of new drug approvals by the regulatory bodies and the patent expirations for major blockbuster drugs are forcing pharmaceutical companies to consider ways in which the time and cost of clinical trials can be reduced without affecting their quality.

Scope

• The report presents various tools and strategies which can help to accelerate a drug to market.
• The report provides detailed information about the need for accelerated drug development.
• The report outlines misconceptions regarding accelerated drug development.
• The report provides information on trends in drug transition and strategies and models adopted to accelerate drug transition through the various stages of development.
• Description of the methods for optimum patient recruitment and retention in a clinical trial.
• Analysis of efficient clinical trial site management so that completion of a trial is done on time.

Reasons to buy

• Develop strategies to implement the use of various technologies for advancing drug discovery and development in an efficient manner.
• Understand the use of biomarkers and surrogate endpoints, improvised clinical trial designs and better recruitment and retention of subjects in clinical trials, in order to avoid drug lags in various phases of development.
• Prioritize design elements of study protocols and balance the overall protocol.
• Ensure efficient clinical trial outcomes by implementing CDISC standards.
• Understand the utility of operationally seamless Phase II/III design for instantaneous transition of the drug from Phase II to Phase III.

Seborrhea Global Clinical Trials Review, H2, 2012

GlobalData''s clinical trial report, “Seborrhea Global Clinical Trials Review, H2, 2012" provides data on the Seborrhea clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Seborrhea. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Seborrhea. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData''s team of industry experts.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies 

Get your copy of this report @  http://www.reportsnreports.com/reports/185534-seborrhea-global-clinical-trials-review-h2-2012.html 

Report Details:
Published: August 2012
No. of Pages: 74 
Price: Single User License:US$ 2500 Corporate User License:US$7500 

   

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Seborrhea 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by BRIC Nations 14
Clinical Trials by G7 Nations 15
Clinical Trials in G7 Nations by Trial Status 16
Clinical Trials by E7 Nations 17
Clinical Trials in E7 Nations by Trial Status 18
Clinical Trials by Phase 19
In Progress Trials by Phase 20
Clinical Trials by Trial Status 21
Unaccomplished Trials of Seborrhea 22
Subjects Recruited Over a Period of Time 23
Prominent Sponsors 24
Top Companies Participating in Seborrhea Therapeutics Clinical Trials 26
Prominent Drug Comparison 28
Clinical Trial Profiles 29
Clinical Trial Overview of Top Companies 29
Astion Pharma A/S 29
Clinical Trial Overview of Astion Pharma A/S 29
Stiefel Laboratories, Inc. 30
Clinical Trial Overview of Stiefel Laboratories, Inc. 30
Pierre Fabre Dermatologie 31
Clinical Trial Overview of Pierre Fabre Dermatologie 31
Laboratoire Labcatal 32
Clinical Trial Overview of Laboratoire Labcatal 32
Aria Aesthetics, Inc. 33
Clinical Trial Overview of Aria Aesthetics, Inc. 33
Dermal Laboratories Limited 34
Clinical Trial Overview of Dermal Laboratories Limited 34
Dermatology Research Center Inc. 35
Clinical Trial Overview of Dermatology Research Center Inc. 35
Montana Pain Management, Inc. 36
Clinical Trial Overview of Montana Pain Management, Inc. 36
Mantecorp Industria Quimica e Farmaceutica Ltda 37
Clinical Trial Overview of Mantecorp Industria Quimica e Farmaceutica Ltda 37
Mimetica Pty Ltd. 38
Clinical Trial Overview of Mimetica Pty Ltd. 38
Maruho Co.,Ltd. 39
Clinical Trial Overview of Maruho Co.,Ltd. 39
Moberg Derma AB 40
Clinical Trial Overview of Moberg Derma AB 40
GlaxoSmithKline plc 41
Clinical Trial Overview of GlaxoSmithKline plc 41
IDEA AG 42
Clinical Trial Overview of IDEA AG 42
Glenmark Pharmaceuticals Ltd. 43
Clinical Trial Overview of Glenmark Pharmaceuticals Ltd. 43
Galderma S.A. 44
Clinical Trial Overview of Galderma S.A. 44
Clinical Trial Overview of Top Universities / Institutes / Hospitals 45
Milton S. Hershey Medical Center 45
Clinical Trial Overview of Milton S. Hershey Medical Center 45
University of Kiel 46
Clinical Trial Overview of University of Kiel 46
Tehran University of Medical Sciences 47
Clinical Trial Overview of Tehran University of Medical Sciences 47
Pusan National Unversity Hospital 48
Clinical Trial Overview of Pusan National Unversity Hospital 48
Federal University of Sao Paulo 49
Clinical Trial Overview of Federal University of Sao Paulo 49
Ascension Health 50
Clinical Trial Overview of Ascension Health 50
Five Key Clinical Profiles 51
Appendix 71
Abbreviations 71
Definitions 71
Research Methodology 72
Secondary Research 72
About GlobalData 73
Contact Us 73
Disclaimer 73
Source 74